Bristol Myers Squibb is looking for a light bulb moment, inking a deal with Autolus Therapeutics that gives the big pharma access to the biotech’s 'safety switch' for CAR-T programs. Under the Autolus agreement terms, BMS—which has two CAR-Ts on the market in the form of Breyanzi and Abecma—will pay the clinical-stage biotech an undisclosed amount upfront for access to its RQR8 safety switch for an initial set of cell therapy programs. Source: Fierce Biotech 4/10/2022